棘白菌素群体药动学模型与特殊人群剂量优化综述
本综述系统检索截至2024年3月的文献,纳入47项棘白菌素群体药动学研究(米卡芬净22项、卡泊芬净13项、阿尼芬净9项、瑞扎芬净3项),聚焦特殊人群剂量优化以最大化PK/PD靶值达成概率。多数模型采用二室模型,体重为清除率和分布容积的显著预测因子,AUC0-24/MIC为最常用疗效靶值;危重症、肥胖、ECMO/CRRT、儿科及免疫抑制患者固定剂量可能不达标,需体重给药或提高负荷/维持剂量,部分高危患者可从TDM获益。
要点
- 危重症、肥胖、ECMO/CRRT、儿科及免疫抑制患者固定剂量可能无法达到PK/PD靶值
- 体重是清除率和分布容积最常报告的显著预测因子,尤其用于估算儿科清除率
- AUC0-24/MIC是评估暴露-疗效关系最广泛报告的PD参数,各棘白菌素靶值不同
核心结论
- 尽管棘白菌素安全性良好且药动学可预测,某些暴露不足风险人群可从TDM获益以预防临床失败
- 在临床实践中实施popPK模型前,应对建议剂量方案进行外部验证并分析人群亚组
研究设计与样本
- 综述检索PubMed、Embase、Web of Science和Scopus从建库至2024年3月,辅以相关文献书目,纳入观察性和前瞻性试验
- 共识别1126篇文章,最终纳入47项研究(米卡芬净22项、卡泊芬净13项、阿尼芬净9项、瑞扎芬净3项)
主要发现
- 78.7%的已开发模型采用二室模型描述棘白菌素药动学参数,也有三室和四室复杂结构模型
- 体重是清除率和分布容积最常报告的显著预测因子,尤其用于估算儿科清除率
- AUC0-24/MIC是评估暴露-疗效关系最广泛报告的PD参数,各棘白菌素提出不同靶值
关键数值与推荐
- 危重症、肥胖、接受ECMO和/或CRRT、儿科、癌症或免疫抑制患者中,说明书推荐的固定剂量策略可能达不到PK/PD靶值
- 针对上述人群提出的策略包括基于体重的给药方案或提高负荷和/或维持剂量
临床怎么用
- 对危重症、肥胖、ECMO/CRRT、儿科及免疫抑制患者,应考虑基于体重给药或提高负荷/维持剂量以达标
- 对暴露不足高危患者可开展TDM以预防临床失败
- 临床实施popPK模型前需外部验证建议剂量方案并分析人群亚组
局限性
- 各模型间估算清除率和分布容积的协变量存在差异
- 建议剂量方案需外部验证并分析人群亚组后方可用于临床实践
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to better understand the pharmacokinetics (PK) of these antifungals. This comprehensive review aimed to summarize popPK models of echinocandins (micafungin, caspofungin, anidulafungin, and rezafungin), by focusing on dosage optimization to maximize the probability of attaining the PK/PD target proposed in special populations. A search in PubMed, Embase, Web of Science, and Scopus, supplemented by the bibliography of relevant articles, was conducted from inception to March 2024, including both observational and prospective trials. A total of 1126 articles were identified, 47 of them were included in the review (22 for micafungin, 13 for caspofungin, 9 for anidulafungin, and 3 for rezafungin). A two-compartment model was more frequently used to describe the PK parameters of echinocandin (78.7% of developed models), although more complex structural models with three and four compartments have also been developed. The covariates to estimate the PK parameters such as clearance (CL) and volume of distribution (Vd) differed between models. Weight total (WT) was the most frequently reported to be a significant predictor for both parameters, especially for estimating the CL in pediatrics. The PD parameter most widely reported assessing the drug exposure-efficacy relationship was the area under the concentration-time curve to minimum inhibitory concentration (MIC) ratio (AUC0-24/MIC) with different targets proposed for each echinocandin. In certain populations such as patients that are critically ill, obese, receiving extracorporeal membrane oxygenation (ECMO) and/or continuous renal replacement therapy (CRRT), or pediatric patients and/or patients with cancer or that are immunocompromised, the fixed dosing strategies recommended in the drug prescribing information may not reach the PK/PD target. For these populations, different strategies have been proposed, such as a dosing regimen based on body weight or increasing the loading and/or maintenance dose. Despite echinocandins' favorable safety profile and predictable PK, certain groups at risk of suboptimal drug exposure can benefit from therapeutic drug monitoring (TDM) to prevent clinical failures. Numerous popPK models of echinocandins have been developed. However, an external validation of the suggested dosing regimens in conjunction with an analysis of population subgroups should be conducted before implementing a popPK model in clinical practice.
引用
- Albanell-Fernández M. Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations. Clin Pharmacokinet. 2024. PMID: 39707078. doi:10.1007/s40262-024-01461-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。